No abstract available.
Biomarkers*

No abstract available.
Biomarkers*

No abstract available.
Biomarkers*

Cerebral small vessel disease （CSVD） is a dynamic vascular disease of the cerebrovascular system caused by various etiologies， resulting in a series of clinical， imaging， and pathological manifestations. With the increase in human life expectancy， CSVD has attracted much attention due to its high incidence and recurrence rates. With the research advances in imaging and neurophysiology， some progress has been made in the pathogenesis， diagnosis， and treatment of CSVD. Currently， researchers have found that the study of blood biomarkers for CSVD may help to achieve early diagnosis and intervention and improve prognosis. In addition， the accessibility， simplicity， and convenience of blood biomarkers make them promising for wide clinical application. This article reviews the research advances in blood biomarkers for CSVD.
Biomarkers

The chronic low-pressure hypoxic environment in high-altitude areas is closely associated with the development of epilepsy， which is associated with various factors such as neuronal death， inflammatory response， and gene expression. In order to quickly diagnose epilepsy in high-altitude areas， the research on epilepsy-related biomarkers has attracted more and more attention. This article reviews the research on biomarkers for epilepsy in high-altitude areas， in order to provide new ideas for the early diagnosis of epilepsy in high-altitude areas and opportunities for exploring potential intervention measures.
Biomarkers

Cognition is the intelligent processing of the brain， which affects the acquisition and realization of knowledge in the body， including learning， memory， thinking， language， emotion， spirit， and other psychological and social activities. Cognitive impairment refers to abnormalities in the processing of higher-order intellectual activities in the brain， such as learning， memory， thinking， and judgment， which leads to severe learning and memory difficulties， and it is often accompanied by pathological developments including aphasia and apraxia， which is mainly caused by Alzheimer disease， cerebrovascular diseases， and traumatic brain injury. At present， the etiology of cognitive impairment remains unclear. Nowadays， with the continuous development of modern science and technology， proteomics technology has been widely used in the field of clinical medical research and can provide a scientific basis for the diagnosis and treatment of diseases and the development of new drugs. This article reviews the research advances in proteomics technologies， humoral proteomics of cognitive disorders， brain tissue proteomics， and proteomics research in cognitive disorders at high altitude， in order to further reveal the application and development of proteomics in cognitive disorders.
Biomarkers

No abstract available.
Biomarkers* ; Metabolism*

No abstract available.
Biomarkers, Tumor

No abstract available.
Ascites* ; Biomarkers*

No abstract available.
Biomarkers ; Humans